{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:27:44Z","timestamp":1760297264767},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1992,2,1]],"date-time":"1992-02-01T00:00:00Z","timestamp":696902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1992,2]]},"DOI":"10.1007\/bf00278480","type":"journal-article","created":{"date-parts":[[2004,10,3]],"date-time":"2004-10-03T17:52:03Z","timestamp":1096825923000},"page":"175-179","source":"Crossref","is-referenced-by-count":5,"title":["Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man"],"prefix":"10.1007","volume":"42","author":[{"given":"R.","family":"Mis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ramis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Forn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"11","volume":"4","author":"M Albors","year":"1987","unstructured":"Albors M, Castellarnau C, Vila L, Sol\ufffd J, Rutllant M (1987) Inhibition of thromboxane production and platelet function by triflusal in healthy volunteers. Rev Farmacol Clin Exp 4: 11?16","journal-title":"Rev Farmacol Clin Exp"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/cpt1976204464","volume":"20","author":"O Borga","year":"1976","unstructured":"Borga O, Odar-Cederlof I, Ringberger V, Norlin A (1976) Protein binding of salicylate in uremic and normal plasma. Clin Pharmacol Ther 20: 464?475","journal-title":"Clin Pharmacol Ther"},{"key":"CR3","first-page":"161","volume":"133","author":"C Davison","year":"1961","unstructured":"Davison C, Smith P (1961) The binding of salicylic acid and related substances to purified proteins. J Pharmacol Exp Ther 133: 161?173","journal-title":"J Pharmacol Exp Ther"},{"key":"CR4","first-page":"273","volume":"10","author":"J Cruz De la","year":"1988","unstructured":"De la Cruz J, Pavia J, Bellido J, Gonz\ufffdlez M, S\ufffdnchez de la Cuesta F (1988) Platelet antiaggregatory effect of triflusal in human whole blood. Methods Find Exp Clin Pharmacol 10: 273?277","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"CR5","first-page":"101","volume":"11","author":"I Demestre","year":"1989","unstructured":"Demestre I, Sagarra R, Palacios G, Roser R (1989) A study of reference parameters in the CFY (remote Sprague-Dawley) rat. Methods Find Exp Clin Pharmacol 11: 101?110","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"CR6","first-page":"357","volume":"7","author":"M Dom\ufffdnguez","year":"1985","unstructured":"Dom\ufffdnguez M, Vacas H, Saez Y, Olabarria I, Velasco A, Iriarte J, Forn J (1985) Effects of triflusal in patients with prosthetic heart valves. Clin Ther 7: 357?360","journal-title":"Clin Ther"},{"key":"CR7","first-page":"89","volume":"8","author":"F Gala","year":"1986","unstructured":"Gala F, Garc\ufffda P, G\ufffdmez J, Garc\ufffda Morato P (1986) Profilaxis de la trombosis venosa profunda en traumatizados. Biol Clin Hematol 8: 89","journal-title":"Biol Clin Hematol"},{"key":"CR8","first-page":"337","volume":"32","author":"J Garc\ufffda-Rafanell","year":"1977","unstructured":"Garc\ufffda-Rafanell J, Morell J (1977) L'effect inhibiteur de l'acide 2-acetoxy-4-trifluoromethylbenzo\ufffdque (triflusal) et de l'aspirine sur l'agr\ufffdgation des plaquettes chez l'homme et le rat. Th\ufffdrapie 32: 337?344","journal-title":"Th\ufffdrapie"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.eurheartj.a059456","volume":"10","author":"P Guiteras","year":"1989","unstructured":"Guiteras P, Altimiras J, Ar\ufffds A, Aug\ufffd J, Bassons T, Bonal J, Caralps J, Castellarnau C, Crexells C, Masotti M, Oriol M, Padr\ufffd J, Rutllant M (1989) Prevention of aortocoronary vein-graft attrition with low dose aspirin and triflusal both associated with dipyridamole: a randomized double-blind, placebo controlled trial. Eur Heart J 10: 159?167","journal-title":"Eur Heart J"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0009-9120(73)80018-9","volume":"6","author":"E Kramer","year":"1973","unstructured":"Kramer E, Routh J (1973) The binding of salicyclic acid and acetylsalicylic acid to human serum albumin. Clin Biochem 6: 98?105","journal-title":"Clin Biochem"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/jps.2600650837","volume":"65","author":"G Levy","year":"1976","unstructured":"Levy G (1976) Effect of plasma protein binding of drugs on duration and intensity of pharmacological activity. J Pharm Sci 65: 1264?1265","journal-title":"J Pharm Sci"},{"key":"CR12","first-page":"978","volume":"238","author":"J Lin","year":"1986","unstructured":"Lin J, Ulm E, Duggan D (1986) Possible mechanism for reduced plasma clearance of diflunisal in rat experimental renal failure. J Pharmacol Exp Ther 238: 978?984","journal-title":"J Pharmacol Exp Ther"},{"key":"CR13","first-page":"791","volume":"25","author":"R Mart\ufffd","year":"1979","unstructured":"Mart\ufffd R, Rocha E, Narvaiza M, Honorato J (1979) Prevention of postoperative deep vein thrombosis (DVT) by triflusal. Study of platelet aggregation, coagulation and DVT detection with 125I-fibrinogen. Curr Ther Res 25: 791?803","journal-title":"Curr Ther Res"},{"key":"CR14","volume-title":"PCNONLIN: User's guide (Vol. 1)","author":"CM Metzler","year":"1985","unstructured":"Metzler CM, Weiner DL (1985) PCNONLIN: User's guide (Vol. 1) Statistical Consultants, Lexington, KY"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/comjnl\/7.4.308","volume":"7","author":"JA Nelder","year":"1965","unstructured":"Nelder JA, Mead R (1965) A simplex method for function minimization. Comput J 7: 308?313","journal-title":"Comput J"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/jps.2600680948","volume":"68","author":"S Oie","year":"1979","unstructured":"Oie S, Tozer TN (1979) Effects of altered plasma protein binding on apparent volume of distribution. J Pharm Sci 68: 1203?1205","journal-title":"J Pharm Sci"},{"key":"CR17","doi-asserted-by":"crossref","unstructured":"Ramis J, Mis R, Forn J (1991a) Pharmacokinetics of triflusal and its main metabolite in rats and dogs. Eur J Drug Metab Pharmacokinet (in press)","DOI":"10.1007\/BF03189970"},{"key":"CR18","doi-asserted-by":"crossref","unstructured":"Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jane F (1991b) Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Eur J Drug Metab Pharmacokinet (in press)","DOI":"10.1007\/BF03189971"},{"key":"CR19","first-page":"11","volume":"7","author":"V Rimbau","year":"1981","unstructured":"Rimbau V, L\ufffdpez R, Fern\ufffdndez A, Forn J (1981) Estudio farmacocin\ufffdtico del triflusal (UR-1501). Arch Farmacol Toxicol 7: 11?16","journal-title":"Arch Farmacol Toxicol"},{"key":"CR20","first-page":"303","volume":"4","author":"HJ Rogers","year":"1981","unstructured":"Rogers HJ, Spector RG, Morrison PJ, Bradbrook ID (1981) Comparative steady state pharmacokinetic study of piroxicam and flurbiprofen in normal subjects. Eur J Rheumatol Inflamm 4: 303?308","journal-title":"Eur J Rheumatol Inflamm"},{"key":"CR21","first-page":"510","volume":"22","author":"ML Rutllant","year":"1977","unstructured":"Rutllant ML, Borell M, Felez J, Diaz JM, Vicente JM, Garc\ufffda-Rafanell J (1977) Effect of triflusal (UR-1501) a potential antithrombotic agent, on blood coagulation and platelet aggregation in man. Curr Ther Res 22: 510?521","journal-title":"Curr Ther Res"},{"key":"CR22","first-page":"767","volume":"16","author":"I Sjoholm","year":"1979","unstructured":"Sjoholm I, Ekman B, Kober A, Ljungstedt-Pahlman I, Seiving B (1979) Binding of drugs to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Pharmacol 16: 767?777","journal-title":"Mol Pharmacol"},{"key":"CR23","first-page":"824","volume":"11","author":"G Sudlow","year":"1975","unstructured":"Sudlow G, Birkett DJ, Wade DN (1975) The characterization of two specific binding sites on human serum albumin. Mol Pharmacol 11: 824?832","journal-title":"Mol Pharmacol"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2165\/00003088-197803020-00004","volume":"3","author":"JP Tillement","year":"1978","unstructured":"Tillement JP, Lhoste F, Giudicelli JF (1978) Diseases and drug protein binding. Clin Pharmacokinet 3: 144?154","journal-title":"Clin Pharmacokinet"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00003088-198308040-00003","volume":"8","author":"R Verbeeck","year":"1983","unstructured":"Verbeeck R, Blackburn JL, Loewen GR (1983) Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 8: 297?331","journal-title":"Clin Pharmacokinet"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00561662","volume":"9","author":"WD Wosilait","year":"1976","unstructured":"Wosilait WD (1976) Theoretical analysis of the binding of salicylate by human serum albumin: The relationship between free and bound drug. Eur J Clin Pharmacol 9: 285?290","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00278480.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00278480\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00278480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T18:27:19Z","timestamp":1554316039000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00278480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992,2]]}},"alternative-id":["BF00278480"],"URL":"https:\/\/doi.org\/10.1007\/bf00278480","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,2]]}}}